SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 5,157.1% in May

SciSparc Ltd. (NASDAQ:SPRC – Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 378,196 shares, an increase of 5,157.1% from the May 14th total of 7,194 shares. Based on an average daily trading volume, of 3,858,258 shares, the days-to-cover ratio is currently 0.1 days. Currently, 67.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of SciSparc in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, SciSparc has an average rating of “Sell”.

Get SciSparc alerts:

View Our Latest Stock Analysis on SciSparc

SciSparc Price Performance

NASDAQ:SPRC traded down $1.11 during mid-day trading on Tuesday, reaching $9.31. The stock had a trading volume of 67,343 shares, compared to its average volume of 711,963. SciSparc has a twelve month low of $2.98 and a twelve month high of $80.10. The business has a 50 day simple moving average of $5.82 and a 200 day simple moving average of $8.64.

SciSparc (NASDAQ:SPRC – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($31.60) EPS for the quarter. The company had revenue of $0.20 million for the quarter.

About SciSparc

(Get Free Report)

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.

Featured Articles

• Five stocks we like better than SciSparc
• The Bank of Mom and Dad Is Booming—3 Stocks to Watch
• Corning Is Paving AI’s Future With Glass
• Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
• Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer

Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.